List of institutions for the national negotiation of drug re-issuance, and accelerated coverage of 13 drugs for cancer treatment
Beijing News Express (Reporter Wu Wei) On June 18, the National Medical Insurance Administration released the list of negotiating drug allocation institutions (the second batch). As of the end of May this year, 73 drugs out of 92 drugs have covered more than 20 provinces across the country , Beijing and other provinces have equipped more than 80 medicines.
The equipment information submitted by the National Medical Insurance Bureau organized by enterprises this time involved a total of 92 drugs, all of which were newly added to the national medical insurance catalog during the 2020 negotiations.
As of May 31, 2021, 92 medicines were deployed in 84,000 designated medical institutions across the country, including 32,000 designated medical institutions and 52,000 designated retail pharmacies.
In terms of varieties, 5 medicines including voronola fumarate green tablets are available in 32 provinces (including the Corps) across the country, and 73 medicines have covered more than 20 provinces.
Focus 1
Accelerated deployment of 13 medical insurance drugs for the treatment of ovarian cancer, liver cancer, breast cancer and other tumors
According to the National Medical Insurance Administration, ovarian cancer, fallopian tube cancer, lymphoma, liver cancer, non-small cell lung cancer, breast cancer, prostate cancer, leukemia and other tumors included in the national medical insurance catalogue for treatment include non-small cell lung cancer with the highest incidence in my country, as well as Breast cancer is the highest incidence among women, and other tumors like liver cancer are also common tumors in our country. Even for some tumors with low incidence, drugs are included in the national medical insurance reimbursement list.
It is reported that before May 31, 2021, the data of these drug distribution institutions has increased to varying degrees compared with April.
These medical institutions and retail pharmacies are located in 31 provinces, municipalities and autonomous regions across the country, providing a very convenient way for patients all over the country to use these drugs included in the medical insurance catalog in a timely manner.
"After being included in the medical insurance catalog, the national medical insurance paid a considerable proportion. At the same time, these drugs also have clear indications, including what kind of patients can be used in what period of treatment, and it is very clear that it also ensures the effective clinical application. Sexuality and rationality.” said Shi Yuankai, chairman of the China Cancer Foundation.
Focus 2
The number of 19 clinically needed drug equipment institutions increased by 68%
This time the drug equipment also showed some characteristics.
According to Zhang Xifan, Director of the Catalogue Division of the Medical Management Department of the National Medical Insurance Administration, the number of institutions with urgent clinical needs of drugs has maintained rapid growth.
Compared with April, the number of 19 institutions with urgent clinical need for medicines increased from 3324 to 5572, an increase of 68%.
At the same time, there are differences in the provision of medicines in different treatment fields. The provision of oncology and chronic diseases is better than that of anti-infection, orthopedics, and parenteral nutrition.
Among the medicines on the market during the same period, the number of Western medicine equipment institutions is higher than that of Chinese patent medicines.
The number of equipped institutions is positively correlated with the time to market for the drug. The longer the time to market, the greater the number of equipped institutions.
In addition, there are differences between different regions.
In terms of the average number of medicines, the eastern, central and western regions showed a downward trend.
In terms of provinces, Jiangsu and Henan are equipped with the most medicines, covering 89 medicines.
13 provinces such as Beijing cover more than 80 medicines, Hainan, Ningxia and other places cover less than 50 medicines, and Tibet only covers 9 medicines.
In the next step, the Medical Insurance Bureau will continue to expand the scope of negotiated drug submissions, optimize the reporting procedures, improve the regular release mechanism, strengthen guidance and scheduling, and promote the landing of negotiated drugs through continuous update and release of the list of negotiated drug allocation agencies.
Interview
Zhang Xifan, Director of the Directory Division of the Medical Management Department of the National Medical Insurance Administration:
Establish an information reporting mechanism for negotiated drug allocation agencies to ease the "difficulty in landing" negotiated drugs
Zhang Xifan, Director of the Catalogue Division of the Medical Management Department of the National Medical Insurance Administration, was interviewed by reporters on June 18 and introduced the recent work of the National Medical Insurance Administration in alleviating the "difficulty in landing" negotiated drugs, and introduced the characteristics of the drug distribution agency.
The Beijing News:
What has the National Medical Insurance Administration done recently to alleviate the "difficulty in landing" negotiated drugs?
Zhang Xifan: In
order to facilitate the timely purchase of drugs under the National Medical Insurance negotiation for the majority of patients and ease the "difficulty in landing" the negotiated drugs, our bureau has organized relevant companies to submit the list of institutions for negotiation of drugs.
What is released today is the list of the second batch of drug distribution institutions.
Regarding the information submission of negotiation drug provision institutions, the National Medical Insurance Bureau firstly establishes a reporting mechanism, secondly organizes enterprises to submit information, and thirdly optimizes the query module.
Regarding the reporting mechanism, we issued notices to relevant companies, putting forward clear requirements on the scope, content format, procedure, time limit, etc. of the drugs to be submitted, and consolidating the main responsibility of the company.
Supervise each company to determine a liaison officer who is responsible for submitting information in accordance with procedures.
At the same time, we organized relevant companies to report on the availability of 92 negotiated drugs.
Arrange a special person to be responsible for scheduling, formal review and communication and coordination, and notify the company to correct and improve the problem as soon as possible, and strive to ensure that the information is comprehensive, accurate and timely.
The Beijing News:
Can you briefly introduce the characteristics of this deployment organization?
Zhang Xifan:
As of May 31, 2021, 92 drugs are available in 84,000 designated medical institutions across the country, including 32,000 designated medical institutions and 52,000 designated retail pharmacies.
From the perspective of the availability, first, the availability of urgently needed clinical medicines continues to improve.
Compared with April, the number of 19 institutions with urgent clinical need for medicines increased from 3324 to 5572, an increase of 68%.
The number of provinces covered has also continued to increase, and the average number of provinces covered has increased from 22 to 25.
Second, there are differences in the provision of medicines in different treatment fields. The provision of drugs for tumors and chronic diseases is better than that of anti-infection and parenteral nutrition.
Third, among the medicines on the market during the same period, the number of western medicines is higher than that of Chinese patent medicines.
Fourth, there is a positive correlation between the number of institutions and the time to market. The longer the time to market, the greater the number of institutions.
Fifth, there are differences between regions.
The average number of medicines in the eastern, central and western regions decreased successively.
Beijing News:
How can an insured patient inquire about the availability of medicines he needs to use?
Zhang Xifan:
We have developed the modules of "Pharmaceutical Companies Online Submitting the Second Batch of National Medical Insurance Negotiation Drug Provision Institutions" and "Negotiating Drug Provision Institution Reference List Inquiry" on the National Medical Insurance Service Platform, and set up an access port on the homepage to facilitate patient inquiries.
sound
Expert: Medicare negotiation drugs will be more in place over time
"Additional equipment is a topic of great concern to the public. Pharmaceutical equipment has market attributes. Although the country negotiates access and is included in the scope of reimbursement. However, enterprises need to be guaranteed under market rules." Shi Luwen, a professor at the School of Pharmacy of Peking University, told reporters , There is a period of time for all medicines to go from enterprise production, through circulation, and then to medical institutions.
As time goes by, it will naturally be better equipped.
Shi Luwen said that even if the equipment is in place, it must be combined with the characteristics of the corresponding medical institutions, the scope of services, and the characteristics of local diseases.
Some hospitals do not have the ability to treat certain diseases, so they will not be equipped. I hope everyone understands.
Beijing News reporter Wu Wei